Benchling is integrating NVIDIA BioNeMo models and NIM microservices into its Benchling AI platform to let scientists run protein structure prediction (OpenFold2) and other biomolecular AI tools directly within Benchling. The move aims to reduce tool switching and infrastructure friction for discovery teams by packaging model microservices into Benchling’s workflow. Meanwhile, Lila Sciences expanded its Series A with an additional $115 million that included Nvidia’s venture arm, bringing total Series A proceeds to $350 million. Lila’s raise underscores rising investor interest in startups combining advanced AI with physical laboratory systems and illustrates how leading AI vendors are deepening partnerships across life‑science toolchains. Taken together, the deals highlight how AI compute and model providers are commercializing through strategic integrations and direct funding, accelerating adoption of biomolecular prediction and generative design in drug discovery workflows.